Deepecho enters Butterfly Garden, leveraging Butterfly Network’s software development kit (SDK) to build and deploy Deepecho AI that will be compatible with Butterfly’s leading imaging platform.

Rabat, Morocco, February 20th, 2024, Deepecho, one of the world leading companies in artificial intelligence (AI) for prenatal care, today announced it has joined Butterfly Garden, an AI Marketplace launched by Butterfly Network, Inc, (“Butterfly”) (NYSE: BFLY) a digital health company transforming care through the power of portable, semiconductor-based ultrasound technology and intuitive software. Under the agreement, Deepecho plans to build an AI guidance solution for antenatal diagnosis for use with Butterfly’s single-probe, whole-body handheld ultrasound system, subject to applicable approvals and authorizations.

Through this collaboration, Deepecho and Butterfly aim to improve the way fetal ultrasound diagnosis is performed by improving its efficiency, accuracy and impact as high-quality maternal and newborn health care are essential health services.

Improving prenatal care is one of the key targets of sustainable development goals worldwide. It is not only an issue of the global South but has become a pressing issue worldwide. The U.S. Center for Disease Control and Prevention latest publication showed that the number of women who died from pregnancy or a pregnancy-related cause in the U.S. in 2021 increased by 40 percent from 2020. This rate of maternal mortality in the U.S. is now the highest since 1965, and the U.S. fares worse than any other industrialized nation.

In August 2023, Butterfly Network launched Butterfly Garden, allowing third-party developers access to its proprietary SDK and APIs to build new AI applications that work in conjunction with Butterfly’s imaging platform, bringing with it access to the largest point-of-care ultrasound customer base. Deepecho, with capabilities to empower clinicians to improve efficiency and accuracy of care, was an ideal match for the program.

“We believe that point-of-care ultrasound (POCUS) will play a key role in the future of ultrasound and especially in prenatal care. Through our DNA we understand the drastic impact this technology can have to democratize access to quality ultrasound for everyone. Butterfly has the leading community of handheld POCUS users worldwide and is a natural key partner for us who shares the same vision for our industry,” Saad Slimani, Chief Medical Officer and Co-Founder of Deepecho.

Darius Shahida, Butterfly Network’s Chief Strategy Officer & Chief Business Development Officer, added, “Butterfly is a company rooted in a commitment to democratizing healthcare by improving access to medical imaging, globally. We’re proud to partner with Deepecho, helping enable their mission to improve the quality and effectiveness of maternal health care. The development of their AI guidance solution for antenatal diagnosis will mark a significant stride towards achieving equitable healthcare worldwide.”

About Deepecho

Deepecho, a healthtech company established in 2020 by Youssef Bouyakhf and Dr. Saad Slimani, is revolutionizing the field of fetal ultrasound through artificial intelligence. The company has pioneered the world’s first comprehensive model for fetal biometry and amniotic fluid volume quantification, achieving results comparable to expert obstetricians as demonstrated in their groundbreaking study published in Nature Communications in November 2023. Deepecho uses Artificial Intelligence and Deep Learning to mimic what a trained sonographer would do and help radiologists and minimally trained clinicians with ultrasound video diagnosis. The company’s current focus is on reducing fetal and maternal mortality rates by making the screening of life-threatening conditions such as preeclampsia, fetal malpresentation, and placenta previa accessible to all.

About Butterfly Network

Founded by Dr. Jonathan Rothberg in 2011, Butterfly Network is a digital health company with a mission is to democratize medical imaging by making high-quality ultrasound affordable, easy-to-use, globally accessible, and intelligently connected, including for the 4.7 billion people around the world lacking access to ultrasound. Butterfly created the world's first handheld single-probe, whole-body ultrasound system using semiconductor technology, Butterfly iQ. The company has continued to innovate, leveraging the benefits of Moore’s Law, to launch its second-generation Butterfly iQ+ in 2020, and third-generation iQ3 in 2024 – each with increased processing power and performance enhancements. The disruptive technology has been recognized by TIME’s Best Inventions, Fast Company’s World Changing Ideas, CNBC Disruptor 50, and MedTech Breakthrough Awards, among other accolades. With its proprietary Ultrasound-on-Chip™ technology, intelligent software, and educational offerings, Butterfly is paving the way to mass adoption of ultrasound for earlier detection and remote management of health conditions around the world. Butterfly devices are commercially available to trained healthcare practitioners in areas including, but not limited to, parts of Africa, Asia, Australia, Europe, the Middle East, North America and South America; to learn more about available countries, visit: www.butterflynetwork.com/choose-your-country.

Deepecho

contact@deepecho.io

Butterfly Business & Technology Inquiries:

Darius Shahida, Chief Strategy & Business Development Officer

dshahida@butterflynetinc.com

Butterfly Media:

Liz Learned, Head of Corporate Communications

media@butterflynetwork.com